<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">CISATRACURIUM BESYLATE</span><br/>(cis-a-tra-kyoo-ri'um)<br/><span class="topboxtradename">Nimbex<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">skeletal muscle relaxant, nondepolarizing</span><br/><b>Prototype: </b>Tubocurarine chloride<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>2 mg/mL, 10 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Cisatracurium is a neuromuscular blocking agent with intermediate onset and duration of action compared with similar agents.
         It binds competitively to cholinergic receptors on motor endplate of neurons, antagonizing the action of acetylcholine.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Antagonism of acetylcholine blocks neuromuscular transmission of nerve impulses. This action can be reversed or antagonized
         by acetylcholinesterase inhibitors (e.g., neostigmine).
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Adjunct to general anesthesia to facilitate tracheal intubation and provide skeletal muscle relaxation during surgery or mechanical
         ventilation.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to cisatracurium or other related agents; rapid-sequence endotracheal intubation. Not studied in children
         
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>History of hemiparesis, electrolyte imbalances, burn patients, neuromuscular diseases (e.g., myasthenia gravis), older adults,
         renal function impairment, pregnancy (category B), lactation.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Intubation</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 0.15 or 0.20 mg/kg<br/><span class="rdage">Child <i><img src="../images/special/greaterorequal.gif"/>2 y</i>
                  				:</span> <span class="rdroute">IV</span> 0.1 mg/kg over 510 sec<br/><br/><span class="indicationtitle">Maintenance</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 0.03 mg/kg q20min prn <i>or</i> 12 mcg/kg/min<br/><span class="rdage">Child <i><img src="../images/special/greaterorequal.gif"/>2 y</i>
                  				:</span> <span class="rdroute">IV</span> 12 mcg/kg/min<br/><br/><span class="indicationtitle">Mechanical Ventilation in ICU</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 3 mcg/kg/min (can range from 0.5 to 10.2 mcg/kg/min)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<ul>
<li>Administer carefully adjusted, individualized doses using a peripheral nerve stimulator to evaluate neuromuscular function.</li>
<li>Give only by or under supervision of expert clinician familiar with the drug's actions and potential complications.</li>
<li>Have immediately available personnel and facilities for resuscitation and life support and an antagonist of cisatracurium.</li>
<li>Refer to manufacturer's guidelines for preparation and administration. Note that 10-mL multiple-dose vials contain benzyl
            alcohol and should not be used with neonates.
         </li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Give undiluted.  <span class="methodtype">IV Infusion:</span> Dilute 10 mg in 95 mL or 40 mg in 80 mL of compatible IV fluid to prepare 0.1 mg/mL or 0.4 mg/mL, respectively, IV solution.
                  Compatible IV fluids include D5W, NS, D5/NS, D5/RL.  <span class="methodtype"> ICU IV Infusion:</span>  Dilute the contents of the 200 mg vial (i.e., 10 mg/mL) in 1000 mL or 500 mL of compatible IV fluid to prepare 0.2 mg/mL
                  or 0.4 g/mL, respectively, IV solutions.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give a single dose over 510 sec.   <span class="methodtype">IV Infusion:</span>  Adjust the rate based on patient's weight.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype"> Solution/additive:</span>
<b> Ketorolac,</b>
<b>propofol,</b>
<b>sodium bicarbonate.</b>
<span class="incompattype"> Y-site:</span>
<b>Amphotericin B,</b>
<b>amphotericin B cholesteryl complex,</b>
<b>cefoperazone,</b>
<b>cefuroxime,</b>
<b>diazepam,</b>
<b>sodium bicarbonate.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Refrigerate vials at 2°8° C (36°46° F). Protect from light. Diluted solutions may be stored
            refrigerated or at room temperature for 24 h.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CV:</span> Bradycardia, hypotension, flushing. <span class="typehead">Respiratory:</span> Bronchospasm. <span class="typehead">Skin:</span> Rash. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead"> Onset:</span> Varies with dose from 1.5 to 3.3 min (higher the dose, faster the onset). <span class="typehead">Peak:</span> Varies with dose from 1.5 to 3.3 min (higher the dose, faster to peak). <span class="typehead"> Duration:</span>  Varies with dose from 46 to 121 min (higher dose, longer recovery time). <span class="typehead"> Metabolism:</span>  Undergoes Hoffman elimination (pH- and temperature-dependent degradation) and hydrolysis by plasma esterases. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 22 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Perform neuromuscular monitoring only on nonparetic limbs.</li>
<li>Time-to-maximum neuromuscular block is <img src="../images/special/asymp.gif"/>1 min slower in the older adult.</li>
<li>Monitor for bradycardia, hypotension, and bronchospasms; monitor ICU patients for spontaneous seizures.</li>
<li>Antagonists should not be given when complete neuromuscular block is present.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>